VBIV.Q Stock Overview
A commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
VBI Vaccines Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.037 |
52 Week High | US$1.35 |
52 Week Low | US$0.02 |
Beta | 2.17 |
11 Month Change | -95.33% |
3 Month Change | -94.19% |
1 Year Change | -97.08% |
33 Year Change | -99.96% |
5 Year Change | -99.82% |
Change since IPO | -99.99% |
Recent News & Updates
Recent updates
VBI Vaccines: Recent Updates Have Fortified My Long-Term Outlook
Sep 22VBI Vaccines gets up to $100M debt funding from K2 HealthVentures
Sep 15Valneva, VBI Vaccines in pact to launch Hep B vaccine in Europe
Sep 08VBI Vaccines down 10% on $300M mixed shelf offering; also ends two equity offerings
Aug 26VBI Vaccines: Recent VBI-1901 Data Supports My Bull Thesis
Jun 17Is VBI Vaccines (NASDAQ:VBIV) A Risky Investment?
Jun 09Is VBI Vaccines (NASDAQ:VBIV) Using Debt Sensibly?
Jan 24Shareholder Returns
VBIV.Q | US Biotechs | US Market | |
---|---|---|---|
7D | -60.9% | -1.0% | 0.2% |
1Y | -97.1% | 9.7% | 17.6% |
Return vs Industry: VBIV.Q underperformed the US Biotechs industry which returned 9.3% over the past year.
Return vs Market: VBIV.Q underperformed the US Market which returned 17.5% over the past year.
Price Volatility
VBIV.Q volatility | |
---|---|
VBIV.Q Average Weekly Movement | 47.2% |
Biotechs Industry Average Movement | 10.6% |
Market Average Movement | 6.2% |
10% most volatile stocks in US Market | 14.8% |
10% least volatile stocks in US Market | 3.2% |
Stable Share Price: VBIV.Q's share price has been volatile over the past 3 months.
Volatility Over Time: VBIV.Q's weekly volatility has increased from 26% to 47% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 135 | Jeff Baxter | www.vbivaccines.com |
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers hepatitis B (HBV) vaccine under the PreHevbrio, PreHevbri, and Sci-B-Vac brand names. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma cancer vaccine immunotherapeutic candidate; VBI-1501, a prophylactic cytomegalovirus vaccine candidate; and VBI-2501 to treat Zika virus.
VBI Vaccines Inc. Fundamentals Summary
VBIV.Q fundamental statistics | |
---|---|
Market cap | US$1.05m |
Earnings (TTM) | -US$83.99m |
Revenue (TTM) | US$9.41m |
0.1x
P/S Ratio0.0x
P/E RatioIs VBIV.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VBIV.Q income statement (TTM) | |
---|---|
Revenue | US$9.41m |
Cost of Revenue | US$11.67m |
Gross Profit | -US$2.26m |
Other Expenses | US$81.73m |
Earnings | -US$83.99m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -2.93 |
Gross Margin | -24.03% |
Net Profit Margin | -892.47% |
Debt/Equity Ratio | -891.6% |
How did VBIV.Q perform over the long term?
See historical performance and comparison